Mipomersen clinical trials

Studies by the year they started

15 studies that test it; most in 2008 (4)

Who runs them

Industry 14 · Other 1

Kastle Therapeutics, LLC (14) · Ludwig-Maximilians - University of Munich (1)

Studies

Open first, then newest update. How each study uses mipomersen is read from its arms, and is right about nine times in ten.

Testing it · 15

• A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein CholesterolCompletedPhase 3Kastle Therapeutics, LLCNCT01475825Written as mipomersen sodium 200 mg
• Measure Liver Fat Content After ISIS 301012 (Mipomersen) AdministrationCompletedPhase 2Kastle Therapeutics, LLCNCT00362180Written as mipomersen
• Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial HypercholesterolemiaCompletedPhase 2Kastle Therapeutics, LLCNCT00477594Written as mipomersen sodium
• Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial HypercholesterolemiaCompletedPhase 3Kastle Therapeutics, LLCNCT00607373Written as mipomersen
• Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic PatientsCompletedPhase 3Kastle Therapeutics, LLCNCT00770146Written as Mipomersen sodium
• Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant SubjectsCompletedPhase 2Kastle Therapeutics, LLCNCT00707746Written as mipomersen
• Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery DiseaseCompletedPhase 3Kastle Therapeutics, LLCNCT00706849Written as mipomersen sodium
• Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on ApheresisCompletedPhase 3Kastle Therapeutics, LLCNCT00794664Written as Mipomersen
• An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-HypercholesterolemiaCompletedPhase 3Kastle Therapeutics, LLCNCT00694109Written as Mipomersen Sodium
• Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy SubjectsCompletedPhase 1Kastle Therapeutics, LLCNCT01414881Written as mipomersen
• Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering TherapyCompletedPhase 2Kastle Therapeutics, LLCNCT00280995Written as ISIS 301012
• A Study to Evaluate 3 Different Dosing Regimens of Mipomersen Administered Via Subcutaneous Injections to Healthy VolunteersCompletedPhase 1Kastle Therapeutics, LLCNCT01061814Written as mipomersen
• A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducted in Healthy SubjectsCompletedPhase 1Kastle Therapeutics, LLCNCT01090661Written as mipomersen sodium
• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of Mipomersen in Japanese Healthy VolunteersCompletedPhase 1Kastle Therapeutics, LLCNCT01299298Written as mipomersen
• Effect of Mipomersen on LDL-Cholesterol Levels in Patients Treated by Regular ApheresisCompletedPhase 3Ludwig-Maximilians - University of MunichNCT01598948Written as mipomersen

Codes

What other systems call mipomersen · ClinicalTrials.gg INT005179

• MeSH (NLM) C524142mipomersenConfirmed ClinicalTrials.gov, NLM
• UNII (FDA) 9GJ8S4GU0MMIPOMERSENConfirmed FDA, NLM
• RxNorm 1367839One source FDA
• NCI Thesaurus C174575MipomersenOne source FDA

Also registered as mipomersen sodium (UNII 18EAY4870E · RxNorm 1367838).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.